...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
【24h】

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer

机译：FGFR1扩增在早期非小细胞肺癌中的预后作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Recently, fibroblast growth factor receptor 1 ( FGFR1 ) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1 -amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.Methods: FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I–II. The FISH results were correlated with clinico-pathological features and overall survival (OS).Results: The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly ( P <0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly ( P =0.0367) worse 5-year OS in patients with an FGFR1- amplified NSCLC.Conclusions: FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.
机译：背景：最近，在肺鳞状细胞癌（SCC）中发现了成纤维细胞生长因子受体1（FGFR1），FGFR1扩增被认为是抗FGFR抑制剂治疗的有希望的预测标记。关于FGFR1扩增和早期非小细胞肺癌（NSCLC）的患病率，预后意义和临床病理特征，只有很少的数据。因此，我们在大量特征明确的早期NSCLC中研究了FGFR1基因状态。方法：使用市售的荧光原位杂交（FISH）探针在组织微阵列（TMA）上评估FGFR1基因状态。该TMA包含329例经切除，福尔马林固定和石蜡包埋的，淋巴结阴性的NSCLC，其UICC阶段为I–II。 FISH结果与临床病理特征和总生存期（OS）相关。结果：FGFR1扩增的患病率为12.5％（41/329），在鳞状细胞癌（SCC）中显着（P <0.0001）高（比腺癌（2.2％）和大细胞癌（13％）高20.7％。多因素分析显示，FGFR1扩增的NSCLC患者5年OS显着恶化（P = 0.0367）。结论：FGFR1扩增在肺早期SCC中很常见，是独立且不良的预后指标。它作为靶向治疗或辅助治疗的预测指标的潜在作用需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号